Moderna (NasdaqGS:MRNA) plans to present Phase 1/2 data for its mRNA-4359 cancer antigen therapy combined with pembrolizumab in advanced melanoma at the 2026 AACR Annual Meeting. The company reports ...
A team from the Max-Planck-Institut für Kohlenforschung, Hokkaido University, and Osaka University has discovered that subtle differences in molecular structure can have a major impact on the ...
A new study by researchers at the Icahn School of Medicine at Mount Sinai overturns a longstanding assumption about how mRNA vaccines generate immunity, revealing that certain non-immune cells help ...
Scientists have discovered the internal shape of tiny drug-delivery particles - called lipid nanoparticles - has a big impact on how well our cells absorb them, paving the way to more efficient ...
The United States may be losing its edge in mRNA technology. The technology, which powered life-saving COVID-19 vaccines and is now rocketing new cancer therapeutics forward, will soon undergo a ...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Moderna (NasdaqGS:MRNA) plans to present Phase 1/2 data ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results